.Attributes Medication, Released online: 30 July 2024 doi:10.1038/ d41591-024-00054-wThe antitoxin-- medicine conjugate (ADC) tisotumab vedotin led to enhanced progression-free and overall survival, resulting in FDA commendation as well as a brand new therapy choice for clients.